Phase II Study of Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder (PTLD)
Latest Information Update: 15 Apr 2024
At a glance
- Drugs Acalabrutinib (Primary) ; Rituximab (Primary)
- Indications Post-transplant lymphoproliferative disorder
- Focus Therapeutic Use
Most Recent Events
- 13 Jun 2023 Status changed from active, no longer recruiting to discontinued.
- 16 Jan 2023 Planned End Date changed from 1 Dec 2022 to 27 Apr 2025.
- 16 Jan 2023 Status changed from recruiting to active, no longer recruiting.